Skip to content

Insider · CIK 0001620564

Daniel Gesua Sive Salvadori

officer

Files at ABT (ABBOTT LABORATORIES). First filing Jan 31, 2025, latest Jan 31, 2025.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $3.1M sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

ABT: ABBOTT LABORATORIES

ABTOct 9, 2026 · close 99.60

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
45Moderate
ABTsell 4
ABBOTT LABORATORIES
$3.1M
23,771 shares
-16%+16% from low-0% from high

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Dec 11, 2025ABT
ABBOTT LABORATORIES
GGift
Common shares without par value
-1,536$123.28$189k132,233Dec 12, 2025
Feb 28, 2025ABT
ABBOTT LABORATORIES
FTax withholding
Common shares without par value
-8,462$135.87$1.1M133,769Mar 4, 2025
Feb 25, 2025ABT
ABBOTT LABORATORIES
AGrant or award
Common shares without par value
+16,534$0.00$0142,231Feb 27, 2025
Feb 25, 2025ABT
ABBOTT LABORATORIES
AGrant or award
Option (right to buy)derivative
+61,580$0.00$061,580Feb 27, 2025
Jan 30, 2025ABT
ABBOTT LABORATORIES
MOption exercise
Common shares without par value
+23,771$38.40$913k149,468Jan 31, 2025
Jan 30, 2025ABT
ABBOTT LABORATORIES
SOpen-market sale
Common shares without par value
-23,771$128.50$3.1M125,697Jan 31, 2025
Jan 30, 2025ABT
ABBOTT LABORATORIES
MOption exercise
Option (right to buy)derivative
-23,771$0.00$00Jan 31, 2025

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Daniel Gesua Sive Salvadori: insider trades and track record | InsiderTell